Table 1.
Incidence proportion and median of patients with PAP-positive (PAP+) and PAP-negative (PAP-).
| PAP+ median (IQR) | No. (%) 5184, 100 | PAP- median (IQR) | No. (%) 3161, 100 | Total | P value | |
|---|---|---|---|---|---|---|
| Age at diagnosis (y) | ||||||
| 30-50 | 48 (45-50) | 161, 3.11 | 48 (46-50) | 131, 4.14 | 292 | 0.365 |
| 51-70 | 63 (58-67) | 2857, 55.11 | 63 (58-67) | 1927, 60.96 | 4784 | 0.968 |
| 71-85 | 76 (73-79) | 1972, 38.04 | 76 (73-78) | 1037, 32.81 | 3009 | ∗0.025 |
| ≥86 | 88.5 (87-91) | 194, 3.74 | 88 (87-90) | 66, 2.09 | 260 | 0.071 |
| Total | 5184, 100 | 3161, 100 | ||||
| Race | ||||||
| White | NA | 3838, 74.73 | NA | 2371, 75.41 | 6209 | NA |
| Black | NA | 1021, 19.88 | NA | 452, 14.38 | 1473 | |
| Asian | NA | 259,5.04 | NA | 304,9.67 | 563 | |
| American Indian | NA | 18, 0.35 | NA | 17, 0.54 | 35 | |
| Total | NA | 5136, 100 | NA | 3144, 100 | 8280 | |
| T | ||||||
| T1 | NA | 1362, 42.30 | NA | 791, 38.44 | 2153 | ∗0.03 |
| T2 | NA | 1229, 38.17 | NA | 855,41.55 | 2084 | |
| T3 | NA | 440,13.66 | NA | 297,14.43 | 737 | |
| T4 | NA | 189, 5.87 | NA | 115,5.9 | 304 | |
| Total | NA | 3220, 100 | NA | 2058, 100 | 5278 | |
| N | ||||||
| N0 | NA | 3804, 98.81 | NA | 2605, 99.09 | 6409 | ∗∗0.005 |
| N1−3 | NA | 46, 1.19 | NA | 24, 0.91 | 38 | |
| Total | NA | 3850, 100 | NA | 2629, 100 | 6479 | |
| M | ||||||
| M0 | NA | 4450, 89.07 | NA | 2974, 95.94 | 7424 | ∗∗<0.001 |
| M1 | NA | 546, 10.93 | NA | 126,4.6 | 672 | |
| Total | NA | 4996, 100 | NA | 3100, 100 | 8096 | |
| Invasion | ||||||
| No invasion | NA | 4185, 3.92 | NA | 2878, 92.87 | 7063 | ∗∗<0.001 |
| Invasion beyond capsule | NA | 242,4.85 | NA | 94, 3.03 | 336 | |
| Distant metastasis | NA | 560, 11.23 | NA | 127, 4.10 | 687 | |
| Total | NA | 4987,100 | NA | 3099, 100 | 8086 | |
| Grade | ||||||
| 1 | NA | 174,3.66 | NA | 143,4.66 | 317 | |
| 2 | NA | 3052, 64.23 | NA | 2197, 71.56 | 5249 | ∗∗<0.001 |
| 3 | NA | 1498, 31.52 | NA | 711,23.16 | 2209 | |
| 4 | NA | 28, 0.59 | NA | 19, 0.62 | 47 | |
| Total | NA | 4752, 100 | NA | 3070, 100 | 7822 | |
| Number of localized tumors | 1.0 (1.0-1.0) | 5184,100 | 1.0 (1.0-2.0) | 3161, 100 | 8345 | ∗∗<0.001 |
| Survival months (all-cause) | 134.0 (63.0-161.0) | 4761, 100 | 143.0 (88.0-166.0) | 2821, 100 | 7582 | ∗∗<0.001 |
| Survival months (prostate cancer-specific) | 47.00 (16.00-90.00) | 963, 100 | 93.00 (52.75-132.00) | 962, 100 | 1925 | ∗∗<0.001 |
| Survival months (postsurgical) | 144.0 (95.0-168.0) | 1642, 100 | 152.0 (125.8-172.0) | 1118, 100 | 2760 | <0.001 |
To value the PAP+/- ratio of each subgroups, the total effective patient number of each group is calculated. As the data were measurement data and ranked data, the Mann-Whitney Sum test was utilized. Abbreviations: + denotes positive; − denotes negative; PAP: prostatic acid phosphatase; TNM: tumor-node-metastasis; No.: number; %: percent; ∗P ≤ 0.05; ∗∗P ≤ 0.01.